RNAi modulation of RSV and therapeutic uses thereof
AssigneeAlnylam Pharmaceuticals, Inc.
InventorRachel Meyers
Life of this patent
Estimating the term…
Abstract
The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses.
Claims28
An isolated dsRNA comprising a sense strand consisting of the nucleotide sequence of SEQ ID NO:
- 283 and an antisense strand consisting of the nucleotide sequence of SEQ ID NO:
- 284.
Dependencies are inferred from the claim text.